Enzymatica Investor Relations Material
Latest events
Study Result
Enzymatica
Q2 2025
17 Jul, 2025
Q1 2025
29 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Enzymatica
Access all reports
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. The company offers ColdZyme, an oral spray for the treatment of common cold; and ear spray for the treatment of otitis media that is primarily intended for infants and small children. Its products are based on its patented enzyme technology, which mimics the body's natural system for managing harmful bacteria. The company markets its products to pharmacies, audiologists, cancer centers, leukemia patients, surgeons, and ENT departments; and online.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
ENZY
Country
🇸🇪 Sweden